Accelerate Licensing & Co-Development Across ADCs, Cell Engagers, BsAbs, TPD & Cell Therapy

Targeting Networking Between Pharma Business Development & Biotech to Drive Feedback, Validation & Partnering Conversations

Demonstrate Differentiation, Understand Pharma’s Strategy, & More Efficiently Secure Deal Conversations

There is no other meeting like the Oncology & Immunology Innovation Partnering & Licensing Summit. This is the only conference specifically built for pharma to efficiently meet, provide feedback on, and compare licensing and co-development opportunities with biotech leaders in a mutually beneficial forum.

Ensuring relevance, favorable pharma-to-biotech ratios, and synergy across attendee interests, this high-impact forum is built from past TPD, ADC, Autoimmunity, and TCE Partnering events.

Built for Depth, Not Dilution:

Why Should You Prioritize this Differentiated Business Development Initiative?

  • Large Pharma: Easily compare pipelines and enabling technologies to fuel future innovation, and understand the scientific context needed for strategic decision making. Best suited for Heads of Business Development, Search & Evaluation, and Asset Scouting for Oncology & Immunology
  • Innovative Biotech: Gain feedback on pitches, data packages, and an understanding of partnership expectations with pharma and investors. Best suited for C-level executives and BD leaders across TPD, ADCS, BsABs, TCEs, and in vivo CAR-Ts
  • Investors & Venture Capital: Demonstrate industry specific thought leadership whilst engaging with both earlier stage programs and validated clinical data, and understanding the direction of pharma’s deal-making strategy for future exits. Best suited for leaders in corporate venture and venture capital.

Marrying collaboration across shared interests whilst delivering modality-specific depth, pharma leaders can assess related programs without dilution; and biotech executives get more efficient, higher-yielding networking than any other conference.

What to Expect?

Pharma Icebreaker Discussion: Insights into Big Pharma’s Wish List

Hear insights into what pharma is looking for directly from business development leads to ensure you share the right information in your private meetings that follow. Does pharma want a lead candidate? What is the key element of differentiation? And what kind of data package is needed to be shown to make a deal? For biotech companies looking to confidently introduce or update their programs, this is a deliberate opportunity for you to understand each pharma’s needs from the outset.

Pharma & Investor Icebreaker Roundtables: Unlock Connections & Break the Ice

Following each pharma and investor panel on the mornings or day one and day two respectively, introduce yourself to attending leaders during the Icebreaker Roundtables. Lay groundwork for follow-up opportunity, ask questions, and hear how other biotech approach conversations when differentiating their pipeline.

One-on-One Partnering System: Schedule Individual Meetings with Other Attendees

Leveraging a one-to-one partnering portal, search the full attendee list, message and pre-schedule meetings in calendars ahead of the conference, and automatically book private meeting spaces: the most efficient way to set yourself up for success.

Presentation Availability During “Showcase Your Science” Sessions in the Agenda

At the intersection of innovative research and business conversations, this forum supports the pitching of biotech pipelines and platforms to pharma and investors. As you register, secure a 15-minute presentation slot. There will be no conflicting content happening to ensure a full and engaged audience, allowing you to generate interest from a large group of potential partners and support any private conversations.

Explore the Full Event Guide

  • A 1-to-5 ratio of biotech to pharma & investors guarantees you face-to-face time with top prospects
  • One-to-One Partnering with the right decision-makers to drive feedback, validation & partnerships
  • Pharma & investors present in >40% of meetings
  • Two formal structured networking sessions, one informal drinks reception
  • Refine your strategy, strengthen your pitch, nurture your relationships to stay front-of-mind after BIO & before JPM
71308 - Oncology & Immunology Innovation Partnering Brochure Image (2)

Statistics from the Neuroscience Innovation Partnering & Licensing Summit, April 2026:

230+

Meetings through the partnering portal, with 50% of meetings involving pharma representatives to fuel future innovation

31%

Meeting acceptance rate versus 11% industry standard, meaning you’re more likely to have successful meetings here than anywhere else

100-120

Attendees from 80-100 companies: 20+ from pharma and investment, giving a 1:5 ratio of buyers to biotech

100%

Director or above ensuring you are connecting with the decision-maker, each time

Attending Companies Include

Audience at Oncology & Immunology Innovation Partnering

Review the Program

Determine whether this highly targeted partnering event can help accelerate your partnering objectives. Explore the event format, expert speaker faculty, and remaining presentation opportunities to see how you can connect with the right decision-makers and maximise your time onsite.
Networking at Oncology & Immunology Innovation Partnering

Elevate Your Brand

Position your brand at the centre of deal-making and gain near-exclusive visibility among senior biotech, pharma, and investment leaders actively seeking new opportunities. Ideal for law firms, banks, CROs, CDMOs, and omics providers looking to strengthen brand recognition through meaningful, high-value interactions.
Speaker at Oncology & Immunology Innovation Partnering

Register to Join

Connect with innovators, investors, and strategic partners at a uniquely timed event designed to bridge the gap between BIO and JPM. Take advantage of early-bird savings, elevate your profile with a presentation slot, and increase your visibility by showcasing your company logo on the event website ahead of the meeting.